RNS Number : 5247A

OptiBiotix Health PLC

26 September 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Launch of novel prebiotic in Europe and Africa

New product will be branded OptiXOS

OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d eveloping compounds to tackle obesity, cardiovascular disease and diabetes, announces it has signed an exclusive distribution agreement with Shandong Longlive Biotechnology Co Ltd ("Longlive") for the distribution of Longlive's unique xylooligosaccharide (" XOS") prebiotic into the human nutrition markets (foods & beverages and supplements) in Europe and Africa. The product will be branded OptiXOS.

Longlive is one of the global technology and market leader in the novel prebiotic XOS. The company has a core capability in corn and corncob processing into various food ingredients such as starch, polyols, sugar replacers, monosaccharides and prebiotic fibres.

XOS is a prebiotic fibre with unique characteristics and benefits compared to other prebiotic fibres commercially available in Europe. One gram of XOS is sufficient to have a marked effect on the growth of healthy favourable gut microbes such as bifidobacteria and lactobacilli. Its superior stability at high temperatures and low pH combined with the small effective dose give it wide applicability within food & beverage applications and extends its reach to supplement applications requiring pills, tablets and capsules. XOS is stable in the harsh environment of the gastrointestinal tract which maximises its effectiveness when it reaches the gut.

XOS also has a complementary effect on the growth and propagation of probiotics such as Lactobacillus plantarum and Lactobacillus rhmanosus (such as LGG). This creates the potential for probiotic companies to boost the health benefits of their existing products and create real differentiation in the market. This application has been researched by OptiBiotix as part of a joint development with DSM (announced 5 April 2016) and is covered by an extensive patent portfolio.

Longlive has been successful in obtaining key regulatory approvals for XOS in the North American market (FDA GRAS and New Dietary Ingredient, Health Canada) and in 2018 obtained EFSA Novel Food approval opening up the European market.

OptiXOS comes with an active a pipeline of customer projects passed on by Longlive and is commercially available to customers with immediate effect. The new logo for the product is displayed below.

René Kamminga, C EO of O pti B i oti x Limited, c o mmented : "XOS is an important addition to OptiBiotix's technology portfolio. It is a building block that will increase our importance in microbiome modulation and act as leverage for our more advanced science based prebiotic solutions in the food & beverage and supplement industry in Europe & Africa. The agreement with Longlive is another step for Optibiotix on its path to in-license or acquire unique technologies to broaden its product portfolio and reinforce our role as leaders in the microbiome field. We look forward to working with the team at Longlive to make this link-up into a significant contributor to our mutual business growth ambitions."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 OptiBiotix Health plc                             www.optibiotix.com 
 Stephen O'Hara, Chief Executive                 Contact via Walbrook 
 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 Cenkos Securities plc (Broker)                    Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 Walbrook PR Ltd                                   Mob: 07876 741 001 
 Anna Dunphy 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

September 26, 2022 02:00 ET (06:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Nov 2022 a Dic 2022 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Dic 2021 a Dic 2022 Clicca qui per i Grafici di Optibiotix Health